6 Reasons Your Peptide Ad Creative Keeps Getting Rejected Before a Human Ever Reviews It

Peptide ad creative rejected on review? These 6 specific asset-level triggers explain why compliant ads still get flagged — and what to fix first.

If your creative is compliant on paper but still disapproved, the problem usually isn’t the claim — it’s something the classifier scored before a human touched the file.

1. Before-and-after visual framing in static images

Google’s image classifier treats side-by-side or sequential body images as implied transformation claims, regardless of overlay text. A product shot flanked by a physique image — even a generic stock photo — scores high enough on the health-transformation model to trigger automatic disapproval. The fix is removing any visual pairing that implies a physical outcome, not just auditing the copy.

2. Overlay text containing percentage or numerical claims

Numbers like “99%” or “3x” burned into an image are read as quantified efficacy claims by optical-character-recognition layers in automated review. This catches brands that correctly avoid those figures in headline fields but embed them in a designed asset. Even “3rd-party tested” with a checkmark graphic has triggered this in restricted health categories.

3. Video thumbnail frames extracted at the wrong second

YouTube and Google Video campaigns auto-extract thumbnail candidates from your video. If frame one or two shows a syringe, vial, or clinical-looking background, the thumbnail classifier flags the asset independently of what the video actually says. Brands running research peptide video ads need to hard-code a clean opening frame — the automated system will not wait to see context.

4. Landing-page keyword echoed in the creative file name or alt tag

Asset metadata is scanned. A file named “bpc-157-healing-peptide.jpg” or carrying that string in an alt attribute can link the creative to a restricted destination keyword and push the asset into a higher-scrutiny queue, accelerating disapproval even on accounts with clean history.

5. Stock imagery flagged by visual similarity to pharma ad templates

High-resolution lab coat, syringe, or molecular imagery from major stock libraries appears in pharmaceutical drug ads. Google’s visual-similarity model associates those images with regulated drug advertising and scores supplement ad creative accordingly. Original or category-neutral photography sidesteps this entirely.

6. Audio transcription triggering health-claim detection in video ads

For video, automated review includes speech-to-text. Phrases like “accelerate recovery,” “increase muscle,” or “reduce inflammation” spoken in a voiceover — even without appearing as text — feed the health-claim classifier and can disapprove an otherwise clean asset. Compliant research peptide video ads need transcript review with the same scrutiny applied to written copy.

Research Amino Marketing’s Creative & Brand service builds static and video assets specifically around these classifier behaviors — structuring visual hierarchy, file metadata, opening frames, and audio scripts so compliant creative actually clears automated review without sacrificing scroll-stopping impact.

Recent Blogs

Launch with growth in mind.

The systems built during a launch — clean tracking, a storefront that converts, processing that holds, retention tied to reorder timing — are what make measurable growth possible later. Every figure below comes from managed peptide accounts, not blended averages from other verticals.